BakerHostetler Continues Business Group Expansion, Adds FDA Partner Winston Kirton in Washington, D.C.

Press Releases / July 6, 2022

WASHINGTON — July 6, 2022

Key takeaways
  • Winston S. Kirton joins BakerHostetler’s Washington office as a partner in the firm’s Business Practice Group, bringing significant experience regarding Food and Drug Administration transactional, regulatory and compliance issues; he joins a stellar FDA team led by experienced practitioners Lee Rosebush and Lance Shea.
  • Kirton’s experience, both in private practice and at Fortune 100 pharmaceutical companies, provides him with key insider perspective, allowing him to deliver start-to-finish counsel to clients on their most pressing transactional, regulatory and compliance matters both in the U.S. and abroad.
  • His arrival is the latest addition to BakerHostetler’s rapidly expanding Business Practice Group, which has added 10 partners in 2022, including national Government Contracts team leader Stephen Ruscus, also based in Washington.
Why this matters

Kirton’s international and domestic experience representing companies across various industries, including biopharmaceutical, medical device, and food and dietary supplements, makes him an immediate asset to both BakerHostetler’s Business Practice Group and the FDA, Products Promotion, and Defense team. His arrival further strengthens the firm’s ability to serve as a one-stop shop for clients with FDA-regulated products or that have FDA issues or questions.

Key quote

“We already have a really talented FDA team at the firm; a lawyer with Winston’s experience, both in big law and in-house, is a tremendous addition to the FDA team. His expertise further strengthens the scope and breadth of the FDA team and the services we can offer clients in this area. We are thrilled to welcome him to our growing Business Practice Group,” said Business Practice Group Chair John Allotta.

About Kirton’s practice

Kirton joins BakerHostetler from an AmLaw 50 firm, where he was a leader in their FDA practice and led the firm’s regulatory due diligence for private equity and M&A transactions involving FDA-regulated entities. He also has worked for some of the world’s most recognizable pharmaceutical and biopharmaceutical brands in the U.S. and London.

Kirton has extensive experience advising clients in regulatory challenges involving FDA-regulated products and services, as well as working alongside companies as they navigate R&D, manufacturing and supply chain, commercialization, and corporate compliance rules and requirements. Additionally, he has a broad range of experience supporting and conducting corporate investigations, both government and internal.

Kirton received his B.S. in biology from Niagara University, his J.D. from Seton Hall University School of Law and his Mini-MBA in biopharma innovation from Rutgers Business School.

Key quote

“We welcome Winston to the firm and to our Washington, D.C., office. He joins an FDA team known for its sophistication and ability to innovate for and with clients. Winston has the background and experience to hit the ground running and to make an immediate impact,” said Jeffrey Paravano, BakerHostetler’s D.C. office managing partner.

For more information on BakerHostetler’s Business Practice Group, visit Connect with us on Twitter at @BakerHostetler or on LinkedIn at @BakerHostetler, @JohnAllotta, @JeffreyParavano or @WinstonKirton.


About BakerHostetler

With hundreds of highly ranked attorneys across multiple practice areas, BakerHostetler helps clients around the world address their most complex and critical business and regulatory issues, delivering sophisticated counsel and outstanding client service. The firm has six core practice groups — Business, Digital Assets and Data Management, Intellectual Property, Labor and Employment, Litigation, and Tax — composed of more than 1,000 lawyers located coast to coast. For more information, visit